For research use only
| Cat No. | ABC-X0221C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human BCR_ABL (F359I) BAF3 Cell Line is designed to explore functional consequences of BCR-ABL mutations in leukemia progression and therapy.
This engineered BAF3 cell line stably expresses the human BCR_ABL gene containing the F359I mutation, achieved through lentiviral integration. The mutation induces IL-3-independent proliferation.
Target
The F359I mutation impacts drug binding and contributes to clinical resistance to imatinib and related compounds. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0221C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Appropriate for screening resistance-breaking TKIs and understanding the biochemical basis of mutation-induced drug insensitivity.